Search results
Results from the WOW.Com Content Network
Zymergen was founded in 2013. [5] by investment banker Joshua Hoffman, biophysicist Zach Serber, and biochemist Jed Dean. [6]All three met while working at Amyris, Inc. [7] The company uses machine learning and artificial intelligence to study and modify microbes which ferment carbon [6] to produce chemicals used in manufacturing consumer goods and pharmaceuticals. [8]
In January 2016, the company received an investment from the Bill & Melinda Gates Foundation's Strategic Innovation Fund to support the development of antimalarial medication based on semi-synthetic artemisinin. [8] In April 2019, the company raised $34-million in private placement of its common stock and warrants.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The field of synthetic biology has not been good to investors. But maybe we've just been looking in the wrong places. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
Synthetic biology, or breaking down life into its basic component parts to create enhanced biological systems, can be likened to writing software that enables life. Or genetic engineering on steroids.
Venter (and Smith)'s previous company, Celera Genomics, was a driving force in the race to sequence the human genome. [9] The firm takes its name from the phrase synthetic genomics which is a scientific discipline of synthetic biology related to the generation of organisms artificially using genetic material. [10] [11]
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.